Primary cutaneous anaplastic large cell lymphoma
Clinical trials for Primary cutaneous anaplastic large cell lymphoma explained in plain language.
Never miss a new study
Get alerted when new Primary cutaneous anaplastic large cell lymphoma trials appear
Sign up with your email to follow new studies for Primary cutaneous anaplastic large cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug duo outsmart resistant T-Cell lymphoma?
Disease control CompletedThis phase II trial is testing whether combining brentuximab vedotin, a targeted antibody-drug conjugate, with lenalidomide, a chemotherapy drug, can shrink tumors in people with T-cell lymphoma that has relapsed or not responded to earlier treatment. The study enrolls adults wit…
Matched conditions: PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA
Phase 2 • Sponsor: John Reneau • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for rare lymphoma: targeted drug shows promise in small trial
Disease control CompletedThis completed Phase 4 trial tested the drug brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma called CD30-positive cutaneous T-cell lymphoma. The goal was to see if the drug could shrink or eliminate cancer for at least 4 months and to check for long-ter…
Matched conditions: PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 26, 2026 18:32 UTC